Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells N-RAS Gene Amplification	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells PTPN11 Gene Mutation	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Somatic Mutation	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Li-Fraumeni Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anbalcabtagene Autoleucel Diffuse Large B-Cell Lymphoma	Hyungwoo Cho	P2	CCC (53)
Anbalcabtagene Autoleucel Primary Central Nervous System Lymphoma	Hyungwoo Cho	P2	CCC (53)
Anti-Bcma/Gprc5D Bispecific Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Anti-Cd19 Car T-Cells Cancer-Associated Retinopathy	KK Women's and Children's Hospital	P2	CCC (53)
Anti-Cd19 Car T-Cells Acute Lymphoblastic Leukemia	KK Women's and Children's Hospital	P2	CCC (53)
Anti-Cd19 Car T-Cells Adult Acute Lymphoblastic Leukemia	KK Women's and Children's Hospital	P2	CCC (53)
Anti-Cd19 Car T-Cells Childhood Acute Lymphoblastic Leukemia	KK Women's and Children's Hospital	P2	CCC (53)
Anti-Cd56 Car T Extranodal Nasal NK/T Cell Lymphoma	The Affiliated Hospital of Xuzhou Medical University	P2	CCC (53)
Anti-Cd56 Car T Aggressive NK-Cell Leukemia	The Affiliated Hospital of Xuzhou Medical University	P2	CCC (53)
Ari-0001 Acute Lymphoblastic Leukemia	Sara V. Latorre	P2	CCC (53)
Ari-0001 High-grade B-cell Lymphoma (HGBCL)	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (53)
Ari-0001 Non-Hodgkin Lymphoma	University Medical Center Groningen	P2	CCC (53)
Ari-0001 Relapsed/Refractory Large B-cell Lymphoma (LBCL)	Ruijin Hospital	P2	CCC (53)
Auto Car T Cell Therapy Acute Lymphoblastic Leukemia	Autolus Limited	P2	CCC (53)
Auto Car T Cell Therapy Diffuse Large B-Cell Lymphoma	Autolus Limited	P2	CCC (53)
Auto Car T Cell Therapy Neoplasm	Autolus Limited	P2	CCC (53)
Auto Car T Cell Therapy T-Cell Non-Hodgkin Lymphoma	Autolus Limited	P2	CCC (53)
Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate Colorectal Cancer	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	P2	CCC (53)
Autologous Hb-Admscs Relapsing-Remitting Multiple Sclerosis	Hope Biosciences Research Foundation	P2	CCC (53)
AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC)-DERIVED T LYMPHOCYTES TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODINGA CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING TWO EPITOPES OF THE HUMAN B CELL MATURATION ANTIGEN (BCMA) UNDER THE CONTROL OF A HUMAN ELONGATION FACTOR 1 ALPHA (EF1.ALPHA.) PROMOTER THE CODING SEQUENCE COMPRISES A HUMAN CD8 ALPHA SIGNAL PEPTIDE (CD8.ALPHA. SP), A BCMA TARGETING DOMAIN CONSISTING OF TWO VARIABLE HEAVY CHAIN-ONLY ANTIBODIES (VHH1 AND VHH2) TARGETING TWO DISTINCT BCMA EPITOPES, A HUMAN CD8 ALPHA HINGE AND TRANSMEMBRANE DOMAIN (CD8.ALPHA. HINGE + TM), A HUMAN CD137 CYTOPLASMIC DOMAIN (4-1BB) AND A HUMAN CD3 ZETA CYTOPLASMIC DOMAIN (CD3.ZETA.). THE VECTOR GENOME CONTAINS A CHIMERIC ROUS SARCOMA VIRUS (RSV)/TRUNCATED 5'LTR AND A SELF-INACTIVATING 3'LTR-SIN (.DELTA.-U3) Plasma Cell Myeloma	Janssen Research & Development, LLC	P2	CCC (53)
AUTOLOGOUS RAPAMYCIN-RESISTANT TH1/TC1 CELLS RAPA-201 Metastatic Melanoma	Rapa Therapeutics LLC	P2	CCC (53)

Showing 251 to 275 of 3,774 assets

PreviousPage 11 of 151Next